☰

Michael A. Curran, Ph.D. - Publications

Affiliations: 
2001 Stanford University, Palo Alto, CA 
Area:
Molecular Biology, Microbiology Biology, Immunology
Tree Info Similar researchers PubMed Report error

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Journal For Immunotherapy of Cancer. 7: 323. PMID 31771649 DOI: 10.1186/S40425-019-0811-X  0.382
2019 Ager CR, Zhang H, Wei Z, Jones P, Curran MA, Di Francesco ME. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorganic & Medicinal Chemistry Letters. 126640. PMID 31500996 DOI: 10.1016/J.Bmcl.2019.126640  0.359
2019 Zamler D, Yen E, Shingu T, Ren J, Kassab C, Liu J, Heimberger A, Hu J, Draetta G, Curran M. IMMU-10. ESTABLISHING EFFECTIVE MODELS FOR IMMUNOTHERAPY IN GBM Neuro-Oncology. 21: vi121-vi121. DOI: 10.1093/Neuonc/Noz175.504  0.373
2015 Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America. 112: E5290-9. PMID 26351680 DOI: 10.1073/Pnas.1514418112  0.322
2015 Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Frontiers in Oncology. 5: 117. PMID 26106583 DOI: 10.3389/Fonc.2015.00117  0.389
2013 Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Journal of Clinical Oncology. 31: 3003-3003. DOI: 10.1200/Jco.2013.31.15_Suppl.3003  0.343
2013 Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O6  0.337
2012 Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43. PMID 22996231 DOI: 10.1007/S13311-012-0144-7  0.4
2012 Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. Plos One. 7: e35222. PMID 22493742 DOI: 10.1371/Journal.Pone.0035222  0.325
2011 Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Plos One. 6: e19499. PMID 21559358 DOI: 10.1371/Journal.Pone.0019499  0.372
2010 Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 4275-80. PMID 20160101 DOI: 10.1073/Pnas.0915174107  0.351
2009 Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Research. 69: 7747-55. PMID 19738077 DOI: 10.1158/0008-5472.Can-08-3289  0.358
2009 Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN. Immune rejection of mouse tumors expressing mutated self. Cancer Research. 69: 3545-53. PMID 19351857 DOI: 10.1158/0008-5472.Can-08-2779  0.372
2008 Fenjves ES, Ochoa MS, Cechin S, Gay-Rabinstein C, Pérez-Alvarez I, Ichii H, Mendez A, Ricordi C, Curran MA. Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. Cell Transplantation. 17: 793-802. PMID 19044206 DOI: 10.3727/096368908786516828  0.434
2006 Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation. 116: 1935-45. PMID 16778987 DOI: 10.1172/Jci27745  0.361
2005 Shai E, Palmon A, Panet A, Marmary Y, Sherman Y, Curran MA, Galun E, Condiotti R. Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 137-43. PMID 15963929 DOI: 10.1016/J.Ymthe.2005.02.022  0.434
2005 Shai E, Condiotti R, Curran MA, Nolan GP, Galun E. 837. Prolonged Gene Expression in Murine Salivary Glands Following FIV-Based Lentiviral Vector Transduction Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.380  0.563
2004 Fenjves ES, Ochoa MS, Gay-Rabinstein C, Ricordi C, Curran MA. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. Cell Transplantation. 13: 489-96. PMID 15565861 DOI: 10.3727/000000004783983710  0.383
2004 Condiotti R, Curran MA, Nolan GP, Giladi H, Ketzinel-Gilad M, Gross E, Galun E. Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochemical and Biophysical Research Communications. 320: 998-1006. PMID 15240147 DOI: 10.1016/J.Bbrc.2004.06.044  0.544
2004 Wolkowicz R, Nolan GP, Curran MA. Lentiviral vectors for the delivery of DNA into mammalian cells. Methods in Molecular Biology (Clifton, N.J.). 246: 391-411. PMID 14970606 DOI: 10.1385/1-59259-650-9:391  0.578
2002 Price MA, Case SS, Carbonaro DA, Yu XJ, Petersen D, Sabo KM, Curran MA, Engel BC, Margarian H, Abkowitz JL, Nolan GP, Kohn DB, Crooks GM. Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 645-52. PMID 12409263 DOI: 10.1016/S1525-0016(02)90725-2  0.576
2002 Curran MA, Ochoa MS, Molano RD, Pileggi A, Inverardi L, Kenyon NS, Nolan GP, Ricordi C, Fenjves ES. Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. Transplantation. 74: 299-306. PMID 12177606 DOI: 10.1097/00007890-200208150-00003  0.535
2002 Curran MA, Nolan GP. Recombinant feline immunodeficiency virus vectors. Preparation and use. Methods in Molecular Medicine. 69: 335-50. PMID 11987787 DOI: 10.1385/1-59259-141-8:335  0.511
2002 Curran MA, Nolan GP. Nonprimate lentiviral vectors. Current Topics in Microbiology and Immunology. 261: 75-105. PMID 11892254 DOI: 10.1007/978-3-642-56114-6_4  0.582
2000 Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 31-8. PMID 10933909 DOI: 10.1006/Mthe.1999.0007  0.582
Show low-probability matches.